NASDAQ:KALV

Kalvista Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Buy KALV

*Your capital is at risk

$26.95

+0.0100 (+0.0371%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

KALV Prediction Chart

KALV Predictions History

Latest community submissions for KALV.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
יונתן ברייטגנד @D799D795D7A0D7AAD79FD791D7A8D799D799D798D792D7A0D793.176092	Oct 20, 2020	$14.00 -17.40%	$16.95	X	82.60%	0
JS Pro	Oct 15, 2020	$14.46 -5.92%	$15.37	X	94.08%	0
JS Pro	Feb 7, 2020	$15.66 +0.71%	$15.55	X	99.29%	4
2poJeff Pro	Feb 7, 2020	$16.48 +5.98%	$15.55	X	94.02%	0
Aldrik Kleinlooh @AldrikKleinlooh.138326	Feb 7, 2020	Bearish	$15.55	X	—	1
NameNotImportant Pro	May 6, 2019	$21.25 -4.62%	$22.28	X	95.38%	0
NameNotImportant Pro	Apr 29, 2019	$24.49 +6.43%	$23.01	X	93.57%	0
JS Pro	Oct 23, 2017	$11.49 -11.75%	$13.02	X	88.20%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for KALV with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT KALVISTA PHARMACEUTICALS INC

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by